Attached files
| file | filename |
|---|---|
| 8-K - PALISADE BIO, INC. | v196357_8k.htm |
Exhibit 99.01
Contact:
|
Meg
McElroy, Shareholder Relations
|
301.366.4960
|
|
Deanne
Eagle, Media Relations
|
917.837.5866
|
|
Susan
Roush, Investor Relations
|
818.222.8330
|
NEURALSTEM
COLLABORATOR TO PRESENT STROKE STUDY
RESULTS
AT STEM CELL & REGENERATIVE MEDICINE CONFERENCE
ROCKVILLE, Maryland,
September 7,
2010 – Neuralstem, Inc. (NYSE
Amex: CUR) announced that Dr. Shinn-Zong Lin, Superintendent at China Medical
University Hospital, will present results from a study entitled, “Intracerebral
Implantation of Adherent Human Neural Stem Cells (or Neurals Progenitor Cells or
"NPCs") to Reverse Motor Deficits in Chronic Stroke Rats,” at the Stem Cells USA
& Regenerative Medical Conference in Philadelphia, PA, on September 14,
2010.
“We are
encouraged by Dr. Lin's findings with our stem cells, which represent a
significant milestone for Neuralstem,” said Richard Garr, Neuralstem CEO and
President. “Unlike our programs in ALS and chronic spinal cord injury, in which
our cells are transplanted into the spinal cord, we will treat stroke-related
movement disorders by direct transplantation into the brain. We are
developing stroke clinical programs both in the U.S. and in Taiwan, and hope to
start our first trial in 2011.”
The company also announced
that CEO and President, Richard Garr, will take part in a panel at the
conference with other industry leaders entitled, “IP Issues and Licensing
Arrangements,” on September 14, 2010. The
panel will discuss intellectual property patent law and licensing issues, as
well as how to manage both IP issues and biotech licensing
agreements.
About
Neuralstem
Neuralstem's
patented technology enables the ability to produce neural stem cells of the
human brain and spinal cord in commercial quantities, and the ability to control
the differentiation of these cells constitutively into mature, physiologically
relevant human neurons and glia. Neuralstem is in a Phase I safety clinical
trial for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's
disease. The company is also targeting major central nervous system diseases in
addition to ALS, including traumatic spinal cord injury, ischemic spastic
paraplegia, and Huntington's disease. The company has also submitted an IND
application to the FDA for a Phase I safety trial in chronic spinal cord
injury.
Through
its proprietary screening technology, Neuralstem has discovered and patented
compounds that may stimulate the brain's capacity to generate new neurons,
possibly reversing the pathologies of some central nervous system conditions.
The company plans to initiate clinical trials to treat Alzheimer's disease and
major depression with its lead compound, as well as pursue additional
indications, including traumatic brain injury, posttraumatic stress syndrome,
stroke and schizophrenia.
For more
information, please go to www.neuralstem.com
Cautionary Statement
Regarding Forward Looking Information
This news
release may contain forward-looking statements made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements in this press
release regarding potential applications of Neuralstem's technologies constitute
forward-looking statements that involve risks and uncertainties, including,
without limitation, risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or regulatory
approvals or clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements.
Additional information on potential factors that could affect our results and
other risks and uncertainties are detailed from time to time in Neuralstem's
periodic reports, including the annual report on Form 10-K for the year ended
December 31, 2009, and in its quarterly report on Form 10-Q for the period ended
June 30, 2010.
# #
#